U
VRDN icon

UBS’s Viridian Therapeutics VRDN Stock Holding History

UBS’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$6K Buy
+6
New +$7.08K ﹤0.01% 9311

Other funds holding VRDN

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

UBS's VRDN Position: Q3 2014 in Review

UBS opened a new position in Viridian Therapeutics (VRDN) in Q3 2014: 6 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #9311 among its holdings.

5 funds tracked by Wall St. Rank hold VRDN as of Q3 2014.

  • UBS held 6 shares of Viridian Therapeutics worth $6K as of Q3 2014.
  • Viridian Therapeutics was a new UBS position in Q3 2014.
  • Viridian Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9311 holding.
  • 5 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.